ArticleFrontiers in public health2022
The Burden of COPD in China and Its Provinces: Findings From the Global Burden of Disease Study 2019.
Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Therapeutic efficacy and pharmacological mechanism of Bailing capsule on chronic obstructive pulmonary disease: a meta-analysis and network pharmacology.Pharmaceutical biology · 2024Pooled it
- The combination of astragalus injection and ambroxol hydrochloride in the adjuvant treatment of COPD: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Disease burden of COPD in the Chinese population: a systematic review.Therapeutic advances in respiratory diseasePooled it
- Pharmacokinetics, Safety and Tolerability of HPP737, a Novel PDE4 Inhibitor, in Healthy Chinese Participants: Phase I Study.Drug design, development and therapy · 2026Trial
- Bu-Fei Yi-Shen Granules Reduce Acute Exacerbations in Patients with GOLD 3-4 COPD: A Randomized Controlled Trial.International journal of chronic obstructive pulmonary disease · 2023Trial
- Risk factors for future exacerbations in patients with COPD treated with dual LABA/LAMA.Annals of medicine · 2026Article
- Efficacy and safety of TQC3403 in patients with chronic obstructive pulmonary disease (COPD): a multicenter, randomized, open-label, phase 3 equivalence trial.Journal of thoracic disease · 2026Article
- Article
- Relationship between the advanced lung cancer inflammation index (ALI) and all-cause and cause-specific mortality among patients with chronic obstructive pulmonary disease (COPD): a population-based study.BMC pulmonary medicine · 2026Article
- Comorbidity of chronic obstructive pulmonary disease and pulmonary tuberculosis: a bibliometric analysis (2011-2025) with narrative review.Journal of thoracic disease · 2026Article
- Article
- Global, regional, and national burden of chronic respiratory diseases among perimenopausal women, 1990-2021: an analysis for the Global Burden of Disease Study 2021.Journal of thoracic disease · 2026Article
- Identification of key influencing factors of health information literacy in COPD patients: a cross-sectional study using a random forest model.BMC pulmonary medicine · 2026Article
- Prevalence and risk factors of airflow obstruction in Southwest China: baseline findings from a multi-center population-based cohort study.BMC pulmonary medicine · 2026Article
- Incidence of acute exacerbation and its related factors among chronic obstructive pulmonary disease patients aged 40 years and older in China.Chinese medical journal pulmonary and critical care medicine · 2026Article
- Non-communicable disease burden in China, 1990-2023: Evidence from the Global Burden of Disease Study 2023.Chinese medical journal · 2026Article
- Integrating Disease Burden and Cost-Effectiveness for Value-Based Prioritisation of COPD Interventions: A Narrative Review.International journal of chronic obstructive pulmonary disease · 2026Review
- Efficacy and Safety of Dupilumab in Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Single-Center Real-World Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Gender Divergence in COPD Phenotypes and Narrowing Urban-Rural Diagnostic Gaps: A Surveillance Study in Chongqing, China, 2020-2024.International journal of chronic obstructive pulmonary disease · 2026Article
- Identifying the Challenges in Self-Management and Preferences for Digital Health Technologies Use Among COPD Patients Based on the CeHRes Roadmap: A Formative Qualitative Study.International journal of chronic obstructive pulmonary disease · 2026Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In China, chronic obstructive pulmonary disease (COPD) was accounted for a quarter of the global COPD population and has become a large economic burden. However, the comprehensive picture of the COPD burden, which could inform health policy, is not readily available for all of the provinces of China. Here, we aimed to describe the burden of COPD in China, providing an up-to-date and comprehensive analysis at the national and provincial levels, and time trends from 1990 to 2019. Following the methodology framework and general analytical strategies used in the GBD 2019, we analyzed the incidence, prevalence, mortality, disability-adjusted life years (DALYs), years lived with disability (YLDs), and years with life lost (YLLs) attributable to COPD across China and the corresponding time trends from 1990 to 2019, stratified by age and province. In order to quantify the secular trends of the burden of COPD, the estimated annual percentage changes were calculated by the linear regression model of age-standardized rates (ASRs) and calendar years. We also presented the contribution of risk factors to COPD-related mortality and DALYs. The association between COPD burden and socio-demographic index (SDI) were also evaluated. From 1990 to 2019, the incidence and prevalence numbers of COPD increased by 61.2 and 67.8%, respectively, whereas the number of deaths and DALYs owing to COPD decreased. The ASRs of COPD burden, including incidence, prevalence, mortality, DALYs, YLDs, and YLLs continuously decreased from 1990 to 2019. The crude rates of COPD burden dramatically increased with age and reached a peak in the older than 95 years age group. In 2019, the leading risk factor for COPD mortality and DALYs was tobacco use in the whole population, but ambient particulate matter pollution was the most significant risk factor in females. At the provincial level, the ASRs of COPD burden was significantly associated with the SDIs, with the highest ASRs in the western provinces with low SDIs. Collectively, our study indicated that COPD remains an important public health problem in China. Geographically targeted considerations should be developed to enhance COPD health and reduce the COPD burden throughout China and in specific provinces.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.